THU-215 Risk of cardiovascular and cerebrovascular events in hepatitis C patients following completion of direct-acting antiviral therapy—A.W. Singer, et al. by Lucinda K. Porter, RN
Study Aims and Results: The purpose of this retrospective research was to compare cardiovascular and cerebrovascular risks of patients completing HCV treatment with DAA regimens compared to untreated HCV patients. The study looked at ten years of data collected from 322,276 adults in the U.S.
Conclusions: This research found that the risk of cardiovascular and cerebrovascular events in HCV patients in treatment using DAAs reduces shortly after therapy is completed. The benefits of curative DAA therapy in reducing extrahepatic complications of HCV may be even greater with longer periods of follow-up.
Editorial Comments: Now that more people are being successfully treated for HCV, it is easier to evaluate the effect of successful treatment. Another study reported a decreased rate of cardiovascular events in patients with compensated HCV cirrhosis after successful treatment. (PS-032 HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients—P. Cacoub, et al)
To read the entire newsletter, click hereShare!